A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Trial Details

NCT ID

NCT07548060

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• sacituzumab tirumotecan

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Histologically or cytologically confirmed non-squamous NSCLC that is locally advanced (Stage ⅢB/ⅢC) or metastatic (Stage Ⅳ) and not amenable to cur…
• Subjects must have received prior EGFR-TKI therapy for locally advanced or metastatic disease and experienced treatment failure (documented radiogr…
• Note: For subjects who have received neoadjuvant or adjuvant EGFR-TKI therapy, if disease progression occurs ≤12 months from the last dose, this EG…
• Male or female subjects aged ≥18 years and ≤75 years who have signed the informed consent form.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.